Treatment
Cell clinical trials
We’re tracking 5,545 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07127289RecruitingPhase 2
Stem cell infusion for low blood counts after CAR-T therapy
This trial tests if giving back your own stored stem cells can help restore low blood cell counts that persist or develop 30 to 90 days after CAR-T therapy for multiple myeloma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07127705Recruiting
How stem cells and immune cells respond to a supplement
This trial tests how a supplement affects your stem cells and immune cells over time. It may help researchers understand if the supplement supports your body's natural defenses.
Klamath Falls, OregonAges 18–75 - NCT05039411RecruitingPhase 1
Cord stem cell treatment for Crohn’s perianal fistulas
This Phase 1 study tests whether donor umbilical cord stem cells are safe for treating fistulas (abnormal tunnels) near the anus in people with Crohn’s disease. It’s mainly looking at safety, and it may help some people’s symptoms if the approach is workable.
Kuala LumpurAges 18 years+ - NCT07118319RecruitingPhase 1
Stem cell therapy safety trial for ALS
This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.
Beijing, Beijing MunicipalityAges 18–75 - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07106684RecruitingPhase 2
Stem cell transplant with car-t and bi-specific antibody for plasma cell leukemia
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07104630RecruitingPhase 2
Pulmonary rehab for advanced lung cancer
This study tests a pulmonary rehabilitation program—special exercises and breathing training—to help people with advanced lung cancer feel less short of breath and improve their daily function and quality of life.
Cleveland, OhioAges 18 years+ - NCT07097207RecruitingPhase 1/Phase 2
Study of CD19CD20-CAR-T for B-cell lymphoma
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT07097935RecruitingPhase 1/Phase 2
Study of HS-10516 combo therapy for advanced kidney cancer
This trial tests a new combination therapy for people with advanced clear cell kidney cancer that has progressed after at least one prior treatment. It aims to see if adding HS-10516 to standard care can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05548621Recruiting
Using shared decision-making tools for kidney cancer care
This study tests whether a shared decision-making approach—using decision aids and guided discussions—helps people make better choices for kidney cancer treatment. It may help you feel more informed and involved when you and your care team decide on next steps.
Nieuwegein, UtrechtAges 18 years+ - NCT07077512RecruitingPhase 2
CAR-T cells plus immunotherapy for advanced B-cell lymphoma
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
GuangzhouAges 18–70 - NCT07078929RecruitingPhase 1
CAR T-cell therapy for children with relapsed or refractory ALL
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
Bangkok, BangkoknoiAges 1–18 - NCT07072169RecruitingPhase 1
Testing an mRNA therapy for relapsed B-cell lymphoma
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07060716Recruiting
Blood test to monitor kidney transplant health
This study is testing a blood test that looks for tiny pieces of the donor's DNA in your blood to check how your new kidney is doing. It may help doctors monitor your transplant and spot problems early, possibly without needing a biopsy.
Los Angeles, CaliforniaAges 18 years+ - NCT07064174Recruiting
Sickle cell kidney research study
This study collects kidney tissue samples from people with sickle cell disease and healthy volunteers to better understand how sickle cell affects the kidneys. If you have sickle cell disease or a related blood disorder, you may help researchers find new ways to protect kidney function.
Dallas, TexasAges 18–65 - NCT07062549RecruitingPhase 1
New imaging agent for metastatic clear cell kidney cancer
This trial tests a new radioactive imaging agent (111In-XYIMSR-01) to see how well it finds clear cell kidney cancer that has spread. It involves a special SPECT/CT scan and may help doctors better see where the cancer is.
Baltimore, MarylandAges 18 years+ - NCT06323525RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new type of CAR-T cell therapy for people with certain B-cell lymphomas that have come back or not responded to treatment. The CAR-T cells are made from a donor and are genetically edited to possibly work better and last longer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07052305RecruitingPhase 1
Testing NT-I7 after CAR T-cell therapy for large B-cell lymphoma
This trial tests whether a drug called NT-I7 (efineptakin alfa) can help people with large B-cell lymphoma who have already received a CAR T-cell treatment like Yescarta or Breyanzi. It aims to boost your immune system's recovery and improve outcomes.
St Louis, MissouriAges 18 years+ - NCT07048314RecruitingPhase 1/Phase 2
Stem cells for erectile dysfunction after prostate surgery
This trial tests if stem cells can help restore erectile function in men who have had prostate cancer surgery (RALP). It is for men with localized, low-risk cancer and good sexual function before surgery.
Houston, TexasAges 40–70 - NCT07044635RecruitingPhase 2
Shorter radiation course after robotic throat surgery
This study tests whether a shorter course of radiation therapy after robotic surgery for HPV-related throat cancer is as effective as the usual longer course. It aims to reduce side effects while maintaining good outcomes.
Salt Lake City, UtahAges 18 years+ - NCT07053670RecruitingPhase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
Wuhang, HubeiAges 18–75 - NCT07046078RecruitingPhase 2
Chemo, radiation, and donor transplant for older adults with high-risk AML
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Seattle, WashingtonAges 18 years+ - NCT04249830Recruiting
Donor stem cell transplant after donor cell targeting in youth
This trial studies a special donor stem cell transplant where the donor’s immune cells are reduced, aiming to lower harmful immune attacks after transplant. It may help children and young adults with certain high-risk blood cancers or rare bone marrow disorders.
Palo Alto, CaliforniaAges 1 month–60 years - NCT06961669Recruiting
CD19 CAR-T cells for B-cell cancers and multiple myeloma
This trial tests a personalized treatment where your own immune cells are modified to target and kill cancer cells that have a protein called CD19. It is for patients with certain types of B-cell lymphoma, B-cell acute leukemia, or multiple myeloma that has come back or not responded to previous treatment.
HefeiAges 3 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,545 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.